215 related articles for article (PubMed ID: 7913890)
1. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.
Ben-Levy R; Paterson HF; Marshall CJ; Yarden Y
EMBO J; 1994 Jul; 13(14):3302-11. PubMed ID: 7913890
[TBL] [Abstract][Full Text] [Related]
2. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.
Akiyama T; Matsuda S; Namba Y; Saito T; Toyoshima K; Yamamoto T
Mol Cell Biol; 1991 Feb; 11(2):833-42. PubMed ID: 1671296
[TBL] [Abstract][Full Text] [Related]
3. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
Guy PM; Carraway KL; Cerione RA
J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
[TBL] [Abstract][Full Text] [Related]
4. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.
Dankort DL; Wang Z; Blackmore V; Moran MF; Muller WJ
Mol Cell Biol; 1997 Sep; 17(9):5410-25. PubMed ID: 9271418
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling.
Sato N; Sakamaki K; Terada N; Arai K; Miyajima A
EMBO J; 1993 Nov; 12(11):4181-9. PubMed ID: 8223433
[TBL] [Abstract][Full Text] [Related]
6. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
[TBL] [Abstract][Full Text] [Related]
7. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
Lehväslaiho H; Lehtola L; Sistonen L; Alitalo K
EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807
[TBL] [Abstract][Full Text] [Related]
8. An incomplete program of cellular tyrosine phosphorylations induced by kinase-defective epidermal growth factor receptors.
Wright JD; Reuter CW; Weber MJ
J Biol Chem; 1995 May; 270(20):12085-93. PubMed ID: 7538132
[TBL] [Abstract][Full Text] [Related]
9. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
Mikami Y; Davis JG; Dobashi K; Dougall WC; Myers JN; Brown VI; Greene MI
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7335-9. PubMed ID: 1354355
[TBL] [Abstract][Full Text] [Related]
10. The role of autophosphorylation in modulation of erbB-2 transforming function.
Segatto O; Lonardo F; Pierce JH; Bottaro DP; Di Fiore PP
New Biol; 1990 Feb; 2(2):187-95. PubMed ID: 1982072
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation.
Galang CK; García-Ramírez J; Solski PA; Westwick JK; Der CJ; Neznanov NN; Oshima RG; Hauser CA
J Biol Chem; 1996 Apr; 271(14):7992-8. PubMed ID: 8626480
[TBL] [Abstract][Full Text] [Related]
12. Modulation of erbB kinase activity and oncogenic potential by single point mutations in the glycine loop of the catalytic domain.
Shu HK; Chang CM; Ravi L; Ling L; Castellano CM; Walter E; Pelley RJ; Kung HJ
Mol Cell Biol; 1994 Oct; 14(10):6868-78. PubMed ID: 7935404
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer.
Engelman JA; Lee RJ; Karnezis A; Bearss DJ; Webster M; Siegel P; Muller WJ; Windle JJ; Pestell RG; Lisanti MP
J Biol Chem; 1998 Aug; 273(32):20448-55. PubMed ID: 9685399
[TBL] [Abstract][Full Text] [Related]
14. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the role of the Shc and Grb2 proteins in signal transduction by the v-ErbB protein.
Meyer S; LaBudda K; McGlade J; Hayman MJ
Mol Cell Biol; 1994 May; 14(5):3253-62. PubMed ID: 7909355
[TBL] [Abstract][Full Text] [Related]
16. junB promoter regulation: Ras mediated transactivation by c-Ets-1 and c-Ets-2.
Coffer P; de Jonge M; Mettouchi A; Binetruy B; Ghysdael J; Kruijer W
Oncogene; 1994 Mar; 9(3):911-21. PubMed ID: 8108135
[TBL] [Abstract][Full Text] [Related]
17. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding.
Fukasawa K; Zhou R; Matten WT; Armstrong AJ; Daar I; Oskarsson M; Sathyanarayana BK; Maclvor L; Wood TG; Vande Woude GF
Oncogene; 1995 Oct; 11(8):1447-57. PubMed ID: 7478569
[TBL] [Abstract][Full Text] [Related]
18. A chimeric EGFR/neu receptor in studies of neu function.
Lehtola L; Lehväslaiho H; Koskinen P; Alitalo K
Cancer Treat Res; 1992; 61():213-28. PubMed ID: 1360234
[No Abstract] [Full Text] [Related]
19. Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins.
Dankort D; Jeyabalan N; Jones N; Dumont DJ; Muller WJ
J Biol Chem; 2001 Oct; 276(42):38921-8. PubMed ID: 11500516
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements of the epidermal growth factor receptor for tyrosine phosphorylation of eps8 and eps15, substrates lacking Src SH2 homology domains.
Alvarez CV; Shon KJ; Miloso M; Beguinot L
J Biol Chem; 1995 Jul; 270(27):16271-6. PubMed ID: 7608194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
